Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2008

View Archived Issues

LY-450139 meets efficacy and safety endpoints in Alzheimer's disease phase II study

Abbott's ABT-869 shows activity against hepatocellular carcinoma in a phase II study

[188Re]-HDD-lipiodol studied for hepatocellular carcinoma in Mongolia

New data on bazedoxifene and bazedoxifene/CE in osteoporosis available

Regeneron and Columbia University sign agreement for VelocImmune mice

Pharmacopeia identifies new lead compound for advancement in alliance with GSK

Auxilium initiates dosing in phase IIb trial of Xiaflex in Peyronie's disease

Recent patent literature describes new anticancer agents

Omeros and The Parkinson's Institute sign collaboration to evaluate a molecular target in PD

Ovation acquires U.S. rights to Xenazine for chorea associated with HD

Merck Serono completes enrollment in REFLEX phase III trial of Rebif in MS

Memory and Roche expand R-3487/MEM-3454 development program

Sanofi pasteur sponsors MEL11 phase II clinical study of ALVAC vaccine in cancer

AMT and Amgen enter license agreement to develop gene therapy for PD

Merck & Co. discontinues license and research collaboration agreement with SurModics

Talecris signs exclusive license agreement with Crucell for PER.C6 technology

Interim results for a novel DNA plasmid BHT-3021 from a phase I/II type 1 diabetes study

Avigen completes multicenter AV-650 phase IIb spasticity trial in MS

EMEA recommends orphan drug designation for AX-200 in spinal cord injury

FDA issues complete response letter to Roche for Actemra BLA

New agents for treating neurological disorders disclosed in recent patents

Recent patents report novel treatments for obesity

Sanofi-aventis Europe intends to raise offer to acquire Zentiva

Enobia receives FDA orphan drug designation for ENB-0040 in hypophosphatasia

EMEA grants orphan drug designation to ATIR for graft-versus-host disease

KeyNeurotek receives EMEA orphan drug designation for KN-38-7271

Anisodamine eliminates NSAID-induced ulcers in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 6, 2025.
Regenxbio’s Duchenne gene therapy data positive as shares falter
BioWorld
Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
EMA warns Ozempic linked to ‘very rare’ side effect
BioWorld
The EMA’s safety committee has issued a warning that the GLP-1 receptor agonist Ozempic (semaglutide, Novo Nordisk A/S) can cause an acute eye condition in which...
Aiatella secures €2M for AI-based cardiovascular imaging tech
BioWorld MedTech
Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds will be used to conduct clinical...